

Transforming solutions for rare diseases

CENTOGENE Corporate Presentation
May 2021



CENTOGENE Snapshot

- Founded in 2006 in Rostock, Germany with other locations in Cambridge, MA and Berlin, Germany
- Listed on Nasdaq in November 2019 (Ticker: CNTG)
- 650+ employees with 2020 annual revenue of €128 million (€49 million in 2019)
- 30+ partnerships with biopharma partners
- ~600k patients in Bio/Databank



Finding and Connecting Rare Disease Patients and their Biology globally...

~600k
Patients




~120
Countries



One
Aim



...to create patient centric, data-driven insights to drastically reduce the heavy burden of rare diseases



CentoCard – a simple logistic & storage solution

CG002610640 CentoCard® CENTOGENE

Please send this sample in frozen additional investigations:
Centogene AG, Schindlerhof 66, 10557 Berlin, Germany • +49 30 2590226-111 | info@centogene.com

PATIENT INFORMATION


Family Name: DOE Gender: ☒ MALE ☐ FEMALE
First Name: JACK
Date of Birth: 16/07/10 Clinical Information: LEUKODYTROPHY, MUSCLE
WEAKNESS, OPTIC ATROPHY
EXOME SEQUENCING

HOSPITAL / PHYSICIAN INFORMATION

Physician: DR. RICHARD ROE
E-mail: SAMPLE@EMAIL.COM
Institution: HOSPITAL FOR CHILDREN
Street / Number: 456 MAIN STREET
ZIP Code: ST 123456 City: ANYTOWN
Country: BRAZIL

We confirm that all relevant legal and medical requirements of our jurisdiction for the analysis of this sample are complied with. Exosome material is donated to Centogene, who will use data and material for further research and product development exclusively on an anonymized basis.

Signature Physician: [Signature]
Signature Patient / Legal Guardian: [Signature]




- ✓ CE-marked
- ✓ Stable for 10+ years
- ✓ Ship via regular mail
- ✓ Available in 30+ languages
- ✓ Barcode for tracking
- ✓ Simple, efficient storage
- ✓ Contains consent to retest biomaterial




Allows for global market coverage

Comprehensive suite of diagnostic solutions from one sample



Creating relevant datasets to foster innovation in value creation use cases for orphan drug discovery and development

Continued improvements in data quantity and data quality¹



EXAMPLES

SORD-related neuropathy

Parkinson's disease


Gaucher disease

¹ Average number of HPO terms (Human Phenotype Ontology) per sample received from Clinical Diagnostics segment customers has increased from 5 to 8 in 2020 versus 2019.


² Quantitative references illustrative per January 2021, reflective of registered individuals in CENTOGENE (laboratory) information systems related to the core business, i.e., Clinical Diagnostics and Pharma segment, but excl. COVID-19.

Continued expansion of platform and repository


Diagnostic Segment – Cumulative Test Requests by type of analysis¹



CentoMD Geographical Regions²



Source Patient Data by Therapeutic Area³



Compare [Centogene Full-Year 2020 Annual Report](#).
1 Represents the cumulative 176,400 test requests (orders) received from our diagnostics segment between Jan. 1, 2016 – Dec. 31, 2020, split by type of analysis. "Standard Genetics" incl. single gene, CNV, mutation quantification products.
2 Represents geographic origin of 430,000 patients included in our CentoMD database 5.8 (per Dec. 31, 2020)
3 Represents the 12 therapeutic areas covered by over 3,941 associated phenotypes and approximately 199,000 individual HPO associations included in our CentoMD database 5.8 (per Dec. 31, 2020)

Pharma segment: Creating value for therapy development

Case study on Parkinson's disease - ROPAD Study & Denali cooperation



10,000+ Participants

Additional Novel Insights

- Rare disease bio/databank offered insights into LRRK2 loss of function – de-risking the development process
- ROPAD Study: created one of the most comprehensive bio/databanks on genetic Parkinson's disease¹ to date
- Potential for identification of new drug targets outside of LRRK2



¹Management estimate; >10% of the 10,000 patients were genetically diagnosed


Case Study: Gaucher disease

Revolutionizing the understanding of rare diseases by connecting patients and their biology

- Publications driving scientific understanding on Gaucher since 2013 >10
- Large cohort of patients diagnosed w. Gaucher disease > 1,800
- Majority of patients with research consent > 55%
- Patient-derived fibroblast samples >130
- Patient-derived tissue-specific cellular models from iPSCs >10
- Patients in LysoProve study for longitudinal follow-ups > 250

Target discovery process:

1. Disease model
Multilayer / Multiomics tools
2. Novel target / data mining
Target identification
3. Compound screening
Drug target validation



AI-based analysis via knowledge graph integrating millions of datapoints

Value creation through CENTOGENE's platform for Pharma partners

Value for Biopharma Industry

Biomarker Development

- Developing biomarkers for high throughput patient testing and providing the ability to monitor patients
 - Support in monitoring progression of disease and demonstrating efficacy for potential therapies
-

Development Acceleration

- Expedited drug screening during discovery
 - Leverage existing CentoMD database & repository to identify patients and aid study enrollment
-

Patient Identification

- Utilize sponsored genetic testing or biomarker to accelerate patient identification to increase commercial adoption
-

Value for Patients

Early Diagnosis

- Expedited treatment through early diagnosis
-

Access to Therapies

- Connecting patients and physicians to currently available and future therapies
-


Personalized Medicine

- Ability to monitor patient's disease state, allowing for individualized dosing and optimal patient outcome
-

New extensive biomarker approach


SINGLE BIOMARKERS

- Lyso-GB1 – like (highly specific)
- Patient finding, diagnostics and monitoring of patients




COMBINATION BIOMARKERS

- 2-10 Biomarkers, combination results in increase of specificity for certain diseases
- Diagnostics and patient finding




PATTERN

- Pattern of complete measurement
- Aims to direct diagnostics & increase diagnostic yield



REFERENCE METABOLOME

- Qualitative & Quantitative characterization of metabolomics features




Biomarker = molecule, n Biomarkers for 1 disease or/and test

FY 2020: Delivering very strong financial results in unprecedented year

Full Year Revenue

(€ Millions)



- Revenues more than doubled in FY 2020 compared to FY 2019, driven by growth from COVID-19 testing
- Pharma revenues decreased 21%, while Clinical Diagnostics revenues (excl. COVID) decreased 19% compared to FY 2019
- Commercial COVID-19 testing contributed €59.8 million in revenues in Q4 2020, up from €27.4 million in Q3 2020

Strong financial performance

Core business recovery


Path forward

- **Revenues** more than doubled in FY 2020 compared to FY 2019, for a record year overall
- Achieved positive and highest annual adjusted EBITDA in company history driven by **COVID-19 testing revenues** in H2 of 2020
- **Diagnostic sample order intakes value** from the core business continued to recover throughout 2020, with Q1 2021 approx. on par with Q1 2020
- Diagnostics recovery and **newly signed Pharma partnership** deals indicate a return to solid core business growth
- **Positive adjusted EBITDA contribution** from commercial COVID-19 allows continuous investments into the Company's rare disease core business
- **Virtual Investor Event** planned for June 22nd, with leadership to outline strategy and direction of the company in its next phase of growth


Revenue grew by >2.5x compared to prior year

Revenues by Segment – Full Year

(€ Millions)



Segment Adjusted EBITDA – Full Year



Status & Outlook

Strong finish to 2020

- Triple digit revenues for FY 2020
- Financial tailwind from COVID-19 testing used to make key strategic investments in core business segments

Diagnostics and Pharma
Segments

- Firm focus on core business in FY 2021: Diagnostics and Pharma segments
- Diagnostic sample order intakes returning to pre-pandemic levels
- Pharma deal momentum continuing from H2 2020 into 2021
- Bio/databank as a key value driver for orphan drug development

Covid-19 Testing

- Volumes robust in 2021 YTD, with pandemic uncertainties still remaining

Save the date


- Virtual Investor Event on June 22, 2021, featuring new and restructured management team

Thank You




FY 2020 revenues by segments


Pharmaceutical Revenues



Diagnostic Revenues



COVID-19 Testing Revenues²



¹ New contracts are defined as contracts signed in the last twelve months
² As COVID-19 testing is a new business for the year, Q3 2020 is used as a reference

Income statement¹

€ Thousands

For the years ended
December 31,

	2019	2020
Revenues	48,780	128,381
Cost of sales	26,005	86,378
Gross profit	22,775	42,003
Research and development expenses	9,590	14,935
General administrative expenses	23,160	37,665
Selling expenses	9,254	7,580
Impairment of financial assets	752	3,738
Other operating income	3,781	2,394
Other operating expenses	1,284	182
Real estate transfer tax expenses	1,200	-
Operating result	(18,684)	(19,703)

¹Selected information

Cash flow & balance sheet¹

		For the year ended December 31, 2019 € Millions	For the year ended December 31, 2020 € Millions	Period-over- period change
Key Items	Cash flow from/(used in) operating activities	(7.8)	8.5	16.3
	Cash flow from/(used in) investing activities	14.2	(16.2)	(30.4)
	Cash flow from financing activities	25.5	14.8	(10.7)

		As of Dec 31, 2019 € Millions	As of Dec 31, 2020 € Millions	Period-over- period change
Key Items	Cash & cash equivalents	41.1	48.2	7.1
	Debt outstanding ²	27.0	24.1	(2.9)
	Net debt / (net cash)	(14.1)	(24.1)	10.0

¹ Selected information

² Debt outstanding includes non-current loans, non-current lease liabilities, current loans and current lease liabilities.

Management focus on value creation in core segments



Andrin Oswald, M.D.
Chief Executive Officer

Diagnostics



Maximilian Schmid
Chief Commercial Officer



Peter Bauer
Chief Genomic Officer

Pharma



Sun Kim
Chief Commercial Officer



Phil Lambert
Chief Scientific Officer

Functions



Nathalie Daste
Chief Human Resources Officer



Volkmar Weckesser
Chief Information Officer



Richard Stoffelen
Chief Financial Officer



Florian Vogel
Chief Process Officer

Key Pharma partnership examples

Drug Discovery



- Data access and research collaboration
- Potential discovery and validation of novel targets for new therapies in rare diseases

Clinical Development



- Help with trial design and patient enrollment
- Shorter development timeline through patient enrollment acceleration (LRRK-2 Parkinson's disease)

Commercialization



- Assist in diagnosis of patients with lysosomal storage disorder
- High throughput testing via proprietary biomarkers